Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo.
We have recently demonstrated in multiple independent population-based longitudinal and cross sectional analyses that the haptoglobin 2-2 genotype is associated with an increased risk for diabetic cardiovascular disease. The chief function of haptoglobin (Hp) is to bind to hemoglobin and thereby prevent hemoglobin-induced oxidative tissue damage. This antioxidant function of haptoglobin is mediated in part by the ability of haptoglobin to prevent the release of iron from hemoglobin on its binding. We hypothesized that there may be diabetes- and haptoglobin genotype-dependent differences in the amount of catalytically active redox active iron derived from hemoglobin. We tested this hypothesis using several complementary approaches both in vitro and in vivo. First, measuring redox active iron associated with haptoglobin-hemoglobin complexes in vitro, we demonstrate a marked increase in redox active iron associated with Hp 2-2-glycohemoglobin complexes. Second, we demonstrate increased oxidative stress in tissue culture cells exposed to haptoglobin 2-2-hemoglobin complexes as opposed to haptoglobin 1-1-hemoglobin complexes, which is inhibitable by desferrioxamine by either a chelation or reduction mechanism. Third, we demonstrate marked diabetes-dependent differences in the amount of redox active iron present in the plasma of mice genetically modified expressing the Hp 2 allele as compared with the Hp 1 allele. Taken together these data implicate redox active iron in the increased susceptibility of individuals with the Hp 2 allele to diabetic vascular disease.
Asleh
Rabea
R
Technion Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Guetta
Julia
J
Kalet-Litman
Shiri
S
Miller-Lotan
Rachel
R
Levy
Andrew P
AP
D000483:Alleles; D000818:Animals; D016466:CHO Cells / Q000187:drug effects / Q000378:metabolism; D006224:Cricetinae; D003412:Cricetulus; D003676:Deferoxamine / Q000494:pharmacology; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D005452:Fluoresceins / Q000494:pharmacology; D005838:Genotype; D005947:Glucose / Q000494:pharmacology; D006442:Glycated Hemoglobin / Q000378:metabolism; D006242:Haptoglobins / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology; D006454:Hemoglobins / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D007501:Iron / Q000737:chemistry / Q000378:metabolism*; D007502:Iron Chelating Agents / Q000494:pharmacology; D007668:Kidney / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D051379:Mice; D008954:Models, Biological; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D011485:Protein Binding; D020033:Protein Isoforms / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology / Q000502:physiology; D011993:Recombinant Fusion Proteins / Q000502:physiology; D013329:Structure-Activity Relationship; D019076:Transgenes
D003676:Deferoxamine; D005452:Fluoresceins; D005947:Glucose; D006442:Glycated Hemoglobin; D006242:Haptoglobins; D006454:Hemoglobins; D007501:Iron; D007502:Iron Chelating Agents; D020033:Protein Isoforms; D011993:Recombinant Fusion Proteins; C035492:haptoglobin-hemoglobin complex; C037631:2',7'-dichlorofluorescein